KCNIP3 and cancer: It is noteworthy that when the DREAM function is lost, cyclin-dependent kinase inhibitor drugs used in cancer treatment, such as Palbociclib, Abemaciclib and Ribociclib, can compensate for defects of this signaling pathway in early stages of cyclin/CDK complexes.